Tekla Life Sciences Investors
HQLNYSEFinancial Services● Active
$16.67
$-0.25(-1.48%)
Market Cap$506901360
P/E Ratio—
52W High$18.46
52W Low$12.34
Tekla Life Sciences Investors (HQL) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · HQL · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-09 | 2023-09 | 2022-09 | 2021-09 | 2020-09 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $85.59M | $22.35M | ($0.10M) | $0.06M | $0.12M |
| Depreciation & Amort. | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Stock-Based Comp. | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Change in Working Capital | ($0.20M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Operations | ($2.32M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Investing Activities | |||||
| Capital Expenditure | ($0.00M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Purchases of Investments | ($314.13M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $339.34M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | $25.21M | $0.00M | $0.00M | $0.00M | $0.00M |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | ($31.63M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Financing | ($31.63M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Free Cash Flow | |||||
| Free Cash Flow | ($2.32M) | $0.00M | $0.00M | $0.00M | $0.00M |
| FCF Margin %(computed) | -2.69% | 0.00% | 0.00% | 0.00% | 0.00% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Tekla Life Sciences Investors data
About Tekla Life Sciences Investors (HQL) Cash Flow Statement
Tekla Life Sciences Investors generated operating cash flow of ($0.00B) and free cash flow of ($0.00B) for 2025 — a FCF margin of -2.69%. Capital expenditure was ($0.00B).
Frequently asked questions
HQL · 4 questionsTekla Life Sciences Investors generated free cash flow of ($0.00B) for 2025, down —% year-over-year.
HQL free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10